Cancers, Vol. 16, Pages 1177: Lung NETs and GEPNETs: One Cancer with Different Origins or Two Distinct Cancers?
eni Peppa Lung neuroendocrine tumors (LNETs) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are two distinct types of neuroendocrine tumors (NETs) that have traditionally been treated as a single entity despite originating from different sources. Although they share certain phenotypic characteristics and the expression of neuroendocrine markers, they exhibit differences in their microenvironment, molecular mutations, and responses to various therapeutic regimens. Recent research has explored the genetic alterations in these tumors, revealing dissimilarities in the frequently mutated genes, the role of EGFR...
Source: Cancers - March 17, 2024 Category: Cancer & Oncology Authors: Georgios Evangelou Ioannis Vamvakaris Anastasia Papafili Maximilian Anagnostakis Melpomeni Peppa Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1178: The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer
This study aims to determine the effects of retinoic acid on arsenite-transformed malignant urothelial cells (UROtsa As), serving as a model for basal muscle-invasive bladder cancer. We treated three independent isolates of arsenite-transformed malignant human urothelial UROtsa cells (UROtsa As) with tretinoin for 48 h. Cell viability, proliferation, and apoptosis were analyzed using crystal violet staining and flow cytometry. mRNA and protein level analyses were performed using RT-qPCR and the Simple Western™ platform, respectively. Tretinoin was found to reduce cell proliferation and urosphere formation, as...
Source: Cancers - March 17, 2024 Category: Cancer & Oncology Authors: Sarmad Al-Marsoummi Aaron A. Mehus Scott H. Garrett Donald A. Sens Seema Somji Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1179: Robotic Bronchoscopy in Lung Cancer Diagnosis
Conclusions: RB is a promising bronchoscopic technique that aims to overcome the limitations of conventional bronchoscopy and improve upon the current techniques of guided bronchoscopy for the investigation of pulmonary nodules. Despite the lower complication rate, current evidence suggests a lower diagnostic yield compared to TTNB. Additional studies are required to adequately evaluate the role of RB in the diagnosis of pulmonary nodules. (Source: Cancers)
Source: Cancers - March 17, 2024 Category: Cancer & Oncology Authors: Vasileios S. Skouras Ioannis Gkiozos Andriani G. Charpidou Konstantinos N. Syrigos Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1180: PIP4K2B Protein Regulation by NSD1 in HPV-Negative Head and Neck Squamous Cell Carcinoma
In conclusion, our findings implicate PIP4K2B as a novel NSD1-dependent protein in HNSCC, suggesting its potential significance for laryngeal cancer cell survival. This insight contributes to our understanding of the molecular landscape in HNSCC and establishes PIP4KB as a promising target for drug development. (Source: Cancers)
Source: Cancers - March 17, 2024 Category: Cancer & Oncology Authors: Iuliia Topchu Igor Bychkov Ekaterina Roshchina Petr Makhov Yanis Boumber Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1168: Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma & mdash;A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group
Conclusion: Both the clinically observed and calculated toxicity rates corroborate the overall low-risk profile of radiotherapy for Hodgkin lymphoma. Further treatment individualization will be attempted in the future. (Source: Cancers)
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Michael Oertel Priska H ölscher Dominik Hering Christopher Kittel Michael Fuchs Uwe Haverkamp Peter Borchmann Hans Theodor Eich Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1169: De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy
Conclusions: BCS after NAT is a feasible and safe option for patients with cT3-4 BC, without adversely affecting long-term oncological outcomes. Identifying predictors of breast conservation can guide surgical decision-making, ensuring that patients receive optimal treatment. (Source: Cancers)
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Corrado Tinterri Erika Barbieri Andrea Sagona Alberto Bottini Giuseppe Canavese Damiano Gentile Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1170: The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer
In this study, we analyzed the expression of ACSLs and investigated the effects of the ACSL inhibitor Triacsin C (TC) in lung cancer. We found that, compared to normal human bronchial epithelial (NHBE) cells, ACSL1, ACSL4, and ACSL6 were highly expressed, while ACSL3 and ACSL5 were lost in the majority of lung cancer cell lines. ACSL activity was associated with the expression levels of the ACSLs. In primary lung tumors, a higher expression of ACSL1, ACSL4, and ACSL5 was significantly correlated with adenocarcinoma (ADC). Moreover, ACSL5 was significantly reversely related to the proliferation marker Ki67 in low-grade tumo...
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Ma Nenkov Berndt Abubrig Schmidt Sandhaus Huber Clement Lang Chen Ga ßler Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1171: Enhancing Leukemia Treatment: The Role of Combined Therapies Based on Amino Acid Starvation
ang Cancer cells demand amino acids beyond their usage as “building blocks” for protein synthesis. As a result, targeting amino acid acquisition and utilization has emerged as a pivotal strategy in cancer treatment. In the setting of leukemia therapy, compelling examples of targeting amino acid metabolism exist at both pre-clinical and clinical stages. This review focuses on summarizing novel insights into the metabolism of glutamine, asparagine, arginine, and tryptophan in leukemias, and providing a comprehensive discussion of perturbing their metabolism to improve the therapeutic outcomes....
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Can Chen Ji Zhang Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1172: Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities
ams Since the 2009 FIGO staging update, focused exclusively on the anatomic extent of disease, there have been several advances in the understanding of the pathologic and molecular features of endometrial cancer. In a significant departure from the 2009 FIGO staging system, the 2023 FIGO staging update integrates both histopathological and molecular classification. With the inclusion of non-anatomic pathologic parameters such as histology, tumor grade, lymphovascular space invasion, and molecular subtype, the 2023 FIGO staging update aims to create more clinically relevant substages that improve prognostic value and al...
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Joy Ogunmuyiwa Vonetta Williams Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1173: A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated Components Using Public Single-Cell RNA-Seq Datasets
hyun Yoon Triple-negative breast cancer (TNBC) is a significant clinical challenge due to its aggressive nature and limited treatment options. In search of new treatment targets, not only single genes but also gene pairs involved in protein interactions, we explored the tumor microenvironment (TME) of TNBC from a retrospective point of view, using public single-cell RNA sequencing datasets. A High-resolution Cell type Annotation Tool, HiCAT, was used first to identify the cell type in 3-level taxonomies. Tumor cells were then identified based on the estimates of copy number variation. With the annotation results, diffe...
Source: Cancers - March 16, 2024 Category: Cancer & Oncology Authors: Minsoo Kim Wonhee Yang Dawon Hong Hye Sung Won Seokhyun Yoon Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1162: Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
Masaharu Hata Durvalumab consolidation after chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) has become the standard of care. Single-center results were examined for treatment outcomes and patterns of pneumonitis in clinical practice. Patients with stage III NSCLC who underwent chemoradiotherapy at our institution (n = 150) were included. The patients were treated with chemoradiotherapy and durvalumab consolidation (Group D, n = 69) or chemoradiotherapy alone (Group N, n = 81). The overall survival (OS), progression-free survival (PFS), and the incidence of and risk factors for 12-month pneumonitis g...
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Mizuki Sato Kazumasa Odagiri Yuya Tabuchi Hiroaki Okamoto Tsuneo Shimokawa Yukiko Nakamura Masaharu Hata Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1163: Pretreatment Circulating HPV16 DNA Viral Load Predicts Risk of Distant Metastasis in Patients with HPV16-Positive Oropharyngeal Cancer
Conclusions: A high VL before treatment indicates patients with a significant risk of DM, and should be used in OPSCC treatment stratification. (Source: Cancers)
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Agnieszka Maria Mazurek Iwona Jab łońska Marek Kentnowski Urszula Kacorzyk Miros ław Śnietura Tomasz Wojciech Rutkowski Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1164: PAX5 Alterations in a Consecutive Childhood B-Cell Acute Lymphoblastic Leukemia Cohort Treated Using the ALL IC-BFM 2009 Protocol
In conclusion, this study provides valuable insights into the presence, frequency, and prognostic significance of diverse PAX5 alterations in B-ALL patients, highlighting the complexity of genetic factors and their impact on patient outcomes. (Source: Cancers)
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Klementina Črepinšek Nika Klobu čar Tine Tesovnik Robert Šket Barbara Jenko Jenko Bizjan Jernej Kova č Marko Kav čič Toma ž Prelog Lidija Kitanovski Janez Jazbec Maru ša Debeljak Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1165: Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer
nna V. Blenda Galectins play a pivotal role in lung cancer oncogenic pathways, influencing apoptosis, angiogenesis, and tumor metastasis. Biomarkers that diagnose, prognose, and guide cancer treatment are crucial, with galectins having the biomarker potential for non-small cell lung cancer (NSCLC). Using enzyme-linked immunosorbent assay (ELISA), we assessed serum galectin-1, -3, and -9 levels in NSCLC patients. A retrospective chart review was performed to examine patient demographics, cancer stage, tumor biology, cancer treatment, and patient outcomes. Galectin levels were then compared across these factors. In this ...
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Hayden Shuster Avery Funkhouser Lorie Allen Moonseong Heo Julie C. Martin W. Jeffery Edenfield Anna V. Blenda Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1166: Mezigdomide & mdash;A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
Cancers, Vol. 16, Pages 1166: Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma Cancers doi: 10.3390/cancers16061166 Authors: Monique A. Hartley-Brown Clifton C. Mo Omar Nadeem Shonali Midha Jacob P. Laubach Paul G. Richardson Mezigomide is an oral cereblon E3 ligase modulator (CELMoD) that is under clinical investigation in patients with relapsed/refractory (RR) multiple myeloma (MM). Like other CELMoD compounds, mezigdomide acts by altering the conformation of cereblon within the cullin 4A ring ligase–cereblon (CRL4CRBN) ...
Source: Cancers - March 15, 2024 Category: Cancer & Oncology Authors: Monique A. Hartley-Brown Clifton C. Mo Omar Nadeem Shonali Midha Jacob P. Laubach Paul G. Richardson Tags: Review Source Type: research